Gene Therapy case Study

The Role of Cryo-Fluorescence Tomography in Analyzing AAV7 & AAV9 Whole-Body Vector Biodistribution

View Case Study

Gene Therapy Case Study

This case study highlights the role of Cryo-Fluorescence Tomography (CFT) in an AAV7 and AAV9 whole animal drug biodistribution study. The study was recently published by REGENXBIO, INC. in the Journal of Virology and explored the potential of AAV7 as a gene therapy vector and compared its biodistribution with AAV9 in mice following intravenous administration (1). CFT was used extensively in this research to analyze the whole-body vector biodistribution and to guide IHC and PCR methods. Learn more below:

Reference 1: Yost SA, Firlar E, Glenn JD, Carroll HB, Foltz S, Giles AR, Egley JM, Firnberg E, Cho S, Nguyen T, Henry WM, Janczura KJ, Bruder J, Liu Y, Danos O, Karumuthil-Melethil S, Pannem S, Yost V, Engelson Y, Kaelber JT, Dimant H, Smith JB, Mercer AC.2023.Characterization and biodistribution of under-employed gene therapy vector AAV7. J Virol97:e01163-23.

On-Demand Webinars

A Novel 3D Approach to Imaging Gene Therapy Expression and Vector Biodistribution

Revolutionizing Immunotherapy Research with 3D, Multiplexed Cryo-Fluorescence Tomography

Additional Content


Introduction Video

Discover More with Cryo-Fluorescence Tomography